



Saving Lives in the time of COVID-19

Case Study of Harm Reduction, Homelessness and Drug Use in Dublin, Ireland

July, 2020

Austin O'Carroll, Tony Duffin and John Collins¹²

¹ Dr Austin O'Carroll is the COVID-19 Clinical Lead for Homelessness in Dublin; Tony Duffin is the CEO of Ana Liffey Drug Project; and Dr John Collins is the Executive Director of the LSE's International Drug Policy Unit.

² This work has been, in part, supported by the LSE Knowledge Exchange and Impact (KEI) fund.

Introduction

Dublin has outperformed even best-case scenarios for COVID-19 mortality among homeless and drug using populations. The experience provides important lessons for policy discussions on the pandemic, as well as broader lessons about pragmatic responses to these key client groups irrespective of COVID-19. The overarching lessons is that when government policy is well coordinated and underpinned by a science-driven and fundamentally pragmatic approach, lives are saved. Within this, the importance of strategic clarity and delivery, housing, lowered thresholds to methadone provision, Benzodiazepine (BZD) provision and Naloxone availability were key determinants of policy success. Further, given the rapid collapse in policy barriers to these interventions that COVID-19 produced, it is important to secure and protect these improved policy responses into the post-COVID-19 era.

When the COVID-19 pandemic reached Dublin, homeless people were identified as a particularly vulnerable group due to their morbidity profile, living conditions and drug use behaviour. A key element of the health services' strategy to protect homeless people from COVID-19 involved the expansion of harm reduction practices that resulted in improved access to methadone treatment; improved access to Naloxone; shifting the management of high dose BZD dependency towards maintenance therapy; and the home delivery of prescription drugs (like methadone and BZDs). Prior to COVID-19 all of these policy choices were limited by regulatory obstacles and uncertain political will. The response to the COVID-19 pandemic has demonstrated some of the unnecessary obstacles placed ahead of potentially lifesaving treatments. Further it has only served to reiterate the value and logic of harm reduction-based drug policies. The purpose of this policy briefing is to outline and explore those initiatives and to consider the future policy implications.

The Onset of COVID-19 in Ireland

On December 31st, 2019, China alerted the World Health Organisation (WHO) to several cases of unusual pneumonia in Wuhan, a port city in the central Hubei province. In February 2020, the WHO officially named this new Coronavirus 'COVID-19' and on 11th March 2020 the WHO declared the COVID-19 outbreak a pandemic. On 12th March 2020 schools in Ireland closed to help reduce the spread of COVID-19. Five days later, on 17th March, Taoiseach Leo Varadkar addressed the nation stating that, 'Never will so many ask so much of so few,' (Bray, 2020) referring to the people on the front line of the response to COVID-19 in Ireland. Ten days later, on 27th March, at midnight, further restrictions designed to reduce the spread of COVID-19 came into place.

Fear and uncertainty permeated the public and professional consciousness. It was also a time that demanded action. It was clear that the best should not be allowed to become the enemy of the good, and this view – that policy makers must respond quickly and not fear taking risks nor making mistakes – drove much of the policy innovation during this time. This was the message from the Executive Director of the WHO's Health Emergencies Programme, Dr Michael Ryan, when he said:

...if you need to be right before you move you will never win. Perfection is the enemy of the good when it comes to emergency management. Speed trumps perfection and the problem in society we have at the moment is everyone is afraid of making a mistake, everyone is afraid of the consequence of error. But the greatest error is not to move, the greatest error is to be paralysed by the fear of failure...(World Health Organisation, 2020)

This crisis elicited a galvanized response amongst the homeless specialised General Practitioner (GP) services, the harm reduction services and the Dublin Homelessness Executive (DRHE). This was then coordinated by the Social Inclusion and Addiction Services of the Health Service Executive (HSE). The quick overarching coordination helped ensure that specific policy responses moved with speed and clarity. We examine some of these in turn.


Housing

At the outset of the policy response there was a very clear sense of what client groups were being targeted. Namely it focused on people who are homeless (Housing Act, 1988), and who use drugs in Dublin city centre, an area with the highest population of these clients (Keane et al., 2018). Very early on, the HSE appointed a Clinical Lead for the COVID-19 Homeless Response. Protocols for identification and immediate testing for homeless clients with symptoms were developed and implemented. Accommodation to allow isolation of positive and suspected cases was rapidly obtained by the DRHE and staff were funded by the HSE. Homeless clients who were deemed vulnerable due to age or medical condition were moved to single occupancy accommodation so that they could be shielded from infection. In addition, homeless accommodation with large numbers of residents saw many transferred in order to decrease occupancy levels and thereby to reduce the risk of spreading COVID-19. By early June:

- over 750 clients had been tested;
- over 330 clients had been placed in isolation;

- over 500 people had been placed in shielding, of whom 340 were shielded in newly obtained units;
- 120 people were moved from high occupancy units to new reduced-occupancy accommodation;
- all rough sleepers were offered accommodation.

The result was that COVID-19 infection and mortality rates were very low with only 63 homeless people diagnosed. There was only one COVID-19 related death, a fraction of what had been predicted (see Figure 1). The expansion of housing provision was an unequivocal success in limiting the direct effects of COVID-19 transmission and infection. Swift, decisive action from all sectors, properly coordinated by public servants, was reflected in this outcome. Policy and central coordination was not sufficient, it was the enabling backdrop that made change possible for many organisations who responded quickly by adapting existing services; redeploying staff; opening new services; and who generally took significant personal risks upon themselves and their loved ones to support the public health response. When these various factors coalesced, including top level institutional and political support, clear coordination coupled with command and control decision making capabilities, existing organisational capacity and a willingness and ability to adapt this, and the sheer dedication and bravery of front line service workers, decisions that would normally take many months or years were effected within days and weeks.



Methadone Provision

Correlations between opiate dependence and negative impacts on life expectancy, physical and mental health and social functioning are well documented. The impacts of stigmatising and repressive policies which undermine public health based approaches have a similarly extensive research underpinning (Csete, 2016, 2014). The benefits of treatment with Opiate Substitution Therapy (OST) for individual users' health and wellbeing are well recognized. As the WHO states,

Opioid agonist maintenance treatment (OAMT) with long-acting opioids (methadone or buprenorphine), which is combined with psychosocial assistance, is the most effective pharmacological intervention for opioid dependence (United Nations, 2020, p. 61).

Alongside the gains for individual clients, there are also demonstrable spill over gains from OST for society in general. These include reduced criminal activity, reduced healthcare costs, lower social welfare costs, and improved social functioning (Garcia-Portilla et al., 2014).

In Dublin there are two main routes for homeless clients to access OST. First, the National Drug Treatment Centre (NDTC), which is a designated OST service for homeless people from across Ireland. The NDTC is based in Dublin City Centre and is the largest treatment centre in the Republic. Prior to the COVID-19 Crisis the NDTC had circa 550 clients with methadone being dispensed on site. Second, GMQ Medical, which was established as a primary care service for homeless people based out of the Granby and Merchants Quay day services.

Prior to the COVID-19 crisis, GMQ Medical had circa 150 clients. However, GMQ Medical had a cap on numbers of patients/hostels it could recruit and NDTC had capacity issues affecting the number of people that they could provide OST to. Due to the large increase in the homeless population in Ireland since the 2007 recession, there has been an imbalance between numbers applying for treatment and those actually being transferred to the community. This resulted in a waiting time for treatment for GMQ Medical of between 12-14 weeks. Delayed treatment admission is associated with numerous risks, including higher rates of intravenous drug usage, overdose, blood borne viral infection and increased mortality (Csete et al., 2016). Nationally, waiting times are determined by a combination of the limits placed on client numbers by clinics, the availability of prescribing doctors and the number of community pharmacy places available. If places are unavailable

clients are placed on a national waiting list (Health Service Executive, n.d.). Long waiting times for homeless people accessing OST are, of course, not unique to Dublin.

It was quickly recognised that one of the main deterrents to individual compliance with isolation and shielding guidelines was substance use. A large number of patients presented who were heroin dependent and were not availing of OST. Immediately, the HSE issued national contingency guidelines allowing for reduced waiting times and removal of caps on recruitment to treatment (Health Service Executive, 2020). In addition, other Drug Treatment Clinics agreed to take on homeless patients resident in hostels in their catchment areas. Waiting times dropped overnight from 12-14 weeks to 2-3 days. An inpatient unit for rapid initiation on to OST for COVID-19 positive, and suspected, patients was established. This four-bedded unit was set up in one of the new homeless Isolation Units where it had access to 24-hour nursing care.

In addition, it was recognized that clients both in isolation and shielding facilities, would be exposed to risk if they had to collect their OST and medication at treatment centres or pharmacies. The EMCDDA had already highlighted that “access to medication is likely to be particularly challenging for those self-isolating, under lock down or in quarantine” (EMCDDA, 2020). Supervision guidelines were amended to allow members of the NDTC and two non-governmental organisation (NGO) Harm Reduction services, Ana Liffey Drug Project and Chrysalis Community Drug Team, to collect clients’ OST and other medication and deliver it at intervals dictated by the client’s risk of overdose.

Thus, the crisis demonstrated that whatever systemic factors had heretofore maintained long waiting times for OST, the COVID-19 impetus saw them removed overnight. Despite an initial EMCDDA warning that due to the COVID-19 pandemic there was, “a risk of reduced access to opioid substitution therapy and other essential medications” (EMCDDA, 2020) waiting times for methadone actually reduced. Overall an extra 160 clients were initiated on treatment by GMQ Medical and 44 by NDTC. Of those started by GMQ Medical, 57 had been sleeping rough prior to initiation of treatment. This was an unequivocal policy success and one from which broader drug policy lessons in Ireland and indeed around the world can be drawn.

BZD Maintenance

There is an increasing problem with high dose BZD dependence both internationally and in Dublin (Darker et al., 2012; Yamamoto et al., 2019). Up to 66% of patients on OST misuse BZDs (Nielsen et al., 2007). In Dublin, 62% of homeless people on OST also misuse street BZDs. BZDs have been implicated in up to 60% internationally, and in Ireland in 92% and

81% of overdose deaths respectively where methadone or heroin were implicated (Dhalla et al., 2009; Health Research Board, 2017). In Dublin, there is a national guideline for BZD detoxification but none for maintenance treatment (Progression Routes Initiative, 2011). Existing guidelines on BZDs recommend detoxification (Health Service Executive, n.d.). Patients on OST get offered either a BZD detox or a maintenance course usually depending on individual clinician preference. This is consistent with international practice, where there is no consensus on the most appropriate clinical intervention (Baandrup et al., 2015; Liebreuz et al., 2010; Soyka, 2010; Tyrer, 2010). The majority of guidelines examined favour gradual detoxification followed by complete abstinence irrespective of the duration and severity of misuse (Lader et al., 2009; Parr et al., 2009). However, in practice, clinicians working in addiction services that have no formal protocol for BZD maintenance often still end up prescribing long term BZDs (Tjagvad et al., 2016).

Prior to the COVID-19 pandemic, GMQ Medical offered BZD detoxes based on the national protocol, but only offered BZD maintenance in occasional cases where previous detoxes had failed and the client was seen to be at high risk from substance misuse. This approach was influenced by the presence of a clear national policy for BZD detox and an absence of a similar policy for BZD maintenance. As COVID-19 infections started to rise in Dublin and clients were placed in Isolation Units and Shielding Units, it was realised that those with high dose BZD dependence were unlikely to remain in their accommodation so increasing their, and other residents', risk of infection. National contingency guidelines emerged recommending that patients in isolation could be offered up to 30mg daily to prevent withdrawals for the period of isolation only. In the homeless sector over 70 people were commenced on BZD maintenance treatment. The homeless sector decided to offer maintenance treatment to patients either in Isolation or Shielding. These medications were collected daily by Ana Liffey Drug Project and Chrysalis Community Drug Teams and delivered to the clients in their accommodation.

The homeless health sector met weekly. It was reported at these meetings that the health and behaviour of clients on maintenance had seemed to improve and that they had complied with the isolation/shielding recommendations. As a result, GMQ Medical reviewed their policy on BZDs and decided to offer BZD maintenance treatment to all patients on OST with established BZD dependency. Dependency was established by interviewing the patient, reviewing their urine results and any history of failed BZD detoxes. A number of clinicians have advocated for maintenance (agonist substitution) treatment for those who have difficulties detoxing or abstaining from BZD misuse (Liebreuz et al., 2010; Wickes et al., 2000). There is evidence supporting the efficacy of this approach (Lingford-Hughes et al., 2004). Weizman et al. found that 79% of patients placed on a maintenance of Clonazepam remained abstinent for at least one year (Weizman et al., 2003). Bakker et al. had been offering BZD maintenance to clients in a GP run methadone clinic in London since 1994. They found those on maintenance had higher treatment

retention and lower mortality than patients who had never been or occasionally been prescribed BZDs (Bakker and Streef, 2017). Eibl et al. found that patients who were not prescribed BZDs as part of routine treatment were twice as likely to leave treatment compared to those on maintenance (Eibl JK et al., 2019). Thus, given this extensive evidence base, GMQ Medical, as a result of the COVID-19 crisis, shifted practice-based policy towards the use of BZD maintenance where clients demonstrated dependency on BZD and wished to have a maintenance treatment.

Naloxone

Naloxone is an opioid antagonist recommended by the WHO for the treatment of opioid overdose (World Health Organisation, 2014). Naloxone is used for the complete or partial reversal of opioid overdose, including respiratory depression. There is a wide body of evidence demonstrating its efficacy (EMCDDA, n.d.). Depending upon the jurisdiction, access to Naloxone varies. Take for example the UK, Ireland's closest English speaking neighbour. In 2005 in the UK, Naloxone was introduced as a medication to be administered, by injection, by anyone for the purpose of saving a life. However, it was classed as a Prescription Only Medicine and was not initially available over the counter but was supplied using a Patient Group Direction (PGD) or in some cases a prescription. In October 2015, there was a regulatory change and it is now much more widely available and accessible without the need for a PGD or prescription (Kirsten Horsburgh, 2018).

In Ireland there are relatively more restrictive pathways for accessing Naloxone (Clarke and Eustace, 2016). This requires a trained keyworker to initially conduct a risk assessment and to educate the client about Naloxone and train them, or their relatives, on how to administer either or both the nasal and injectable forms of Naloxone. Once this is completed the client requires a doctor (usually their own GP, a GP working in specialised homeless services or an OST addiction prescriber) to issue a prescription for the Naloxone. Due to the scheduling of Naloxone in Ireland the person to whom it is prescribed must not give the Naloxone to anyone else to hold for them. However, the HSE did allow for GPs to issue prescriptions retrospectively within a 24 hour period to allow, in particular, for the administration of Naloxone in an overdose scenario (Author's Private Communication, HSE).

With time, it emerged that staff working in homeless services were encountering people who had overdosed, but to whom Naloxone had not been prescribed. It was decided that in these situations, homeless emergency accommodation providers could administer Naloxone as long as the name and date of birth of the person to whom Naloxone was administered was sent to a GP within 72 hours. The GP would then issue a prescription. It was felt that this sufficiently adhered to the regulatory requirements under controlled drug scheduling.

On 26th March, 2020, National contingency guidelines were published, by the HSE, for anyone who was working with people who use drugs (PWUD). It recognised the urgency of the situation and included guidance on Naloxone, recommending that every individual in

receipt of OST and in contact with treatment providers should be offered and encouraged to take a supply of Naloxone. Further it explained that Naloxone was to be administered by a person trained in using the product; and that in the current crisis, injectable Naloxone was to be used. The intranasal product was to be avoided and if using the intranasal product, precautions were to be taken (Health Service Executive, 2020).

Recognising the increased risk of overdose during the COVID-19 crisis the process was quickly adapted to expand access to Naloxone to those most at risk (Health Service Executive, 2020). Naloxone packs were taken out by Ana Liffey Drug Project when delivering their Needle and Syringe Programme (NSP). A person engaging with the outreach NSP was assessed by Ana Liffey Drug Project; who briefed them and/or their partner/companion on the process of using Naloxone and gave them the Naloxone. The names and date of birth were later provided to a GP who issued the prescription for Naloxone retrospectively.

Conclusion

This policy briefing highlights three changes to practice during the COVID-19 crisis . Two of those changes (the removal of barriers to rapid access to methadone and the expanded distribution of Naloxone) were such that they resulted in the removal of barriers to the implementation of national policy. The question remains as to why the barriers existed prior to the crisis. The epidemic created an overwhelming public health argument for the facilitation of immediate access to OST and Naloxone. However, a strong public health argument for having no waiting lists for OST and improved Naloxone distribution to PWUD existed prior to and independent of COVID-19.

It is noteworthy that in the field of Irish medicine the COVID-19 crisis facilitated a number of practice changes that had persuasive arguments in their favour prior to COVID-19 e.g. emailed prescriptions, electronic social welfare certificates, teleconsultations etc. Why it took a pandemic to overcome barriers to seemingly obvious practice reforms is difficult to discern. Possibilities include the effect of the fear and uncertainty that was palpable as COVID-19 infection spread across the nation; the unification of the health service with a clear single mission i.e. to reduce the transmission of infection; or more controversially, the fact that the public health arguments in favour of harm reduction related mainly to the protection of PWUD whereas the public health arguments that arose during the COVID-19 crisis related to protecting the public at large.

Meanwhile, the shift of some services to using BZD maintenance resulted from the gathering of observations from field workers combined with a review of the evidence concerning BZD maintenance. This has resulted in a change in practice that requires ongoing evaluation.

In summary, the COVID-19 crisis acted as a catalyst for changes in the delivery of harm reduction measures to homeless PWUD. Some of these changes enabled the full implementation of national policy objectives in relation to OST and Naloxone interventions and the expansion of BZD maintenance treatment for patients with high dose BZD dependency. We recommend that practices continue to deliver on OST and Naloxone policy objectives and that policy makers review the evidence on BZD maintenance treatment. We further encourage international jurisdictions to examine the case study highlighted here to see if there are any lessons relevant for their immediate efforts to reduce COVID-19 transmission and save lives. Longer-term, we view the COVID-19 experience as a potentially important milestone in the development of national drug policies.

Bibliography:

- Baandrup, L., Ebdrup, B.H., Lindschou, J., Gluud, C., Glenthøj, B.Y., 2015. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. *Cochrane Database Syst. Rev.* 2015. <https://doi.org/10.1002/14651858.CD011481>
- Bakker, A., Streef, E., 2017. Benzodiazepine maintenance in opiate substitution treatment: Good or bad? A retrospective primary care case-note review. *J. Psychopharmacol. (Oxf.)* 31, 62–66. <https://doi.org/10.1177/0269881116675508>
- Bray, J., 2020. Coronavirus: Varadkar addresses nation and says crisis may last months [WWW Document]. *Ir. Times*. URL <https://www.irishtimes.com/news/ireland/irish-news/coronavirus-varadkar-addresses-nation-and-says-crisis-may-last-months-1.4205373> (accessed 6.22.20).
- Clarke, A., Eustace, A., 2016. Evaluation of the HSE Naloxone Demonstration Project. Health Service Executive, Dublin.
- Csete, J., 2016. Public Health Research in a Time of Changing Drug Policy: Possibilities for Recovery?, in: Collins, J., Soderholm, A. (Eds.), *After the Drug Wars: Report of the LSE Expert Group on the Economics of Drug Policy*. LSE IDEAS, London.
- Csete, J., 2014. Costs and Benefits of Drug-Related Health Services, in: Collins, J. (Ed.), *Ending the Drug Wars: Report of the LSE Expert Group on the Economics of Drug Policy*. LSE IDEAS, London.
- Csete, J., Kamarulzaman, A., Kazatchkine, M., Altice, F., Balicki, M., Buxton, J., Cepeda, J., Comfort, M., Goosby, E., Goulão, J., Hart, C., Kerr, T., Lajous, A.M., Lewis, S., Martin, N., Mejía, D., Camacho, A., Mathieson, D., Obot, I., Ogunrombi, A., Sherman, S., Stone, J., Vallath, N., Vickerman, P., Zábanský, T., Beyrer, C., 2016. Public health and international drug policy. *The Lancet*.
- Darker, C.D., Sweeney, B.P., Barry, J.M., Farrell, M.F., 2012. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. *Cochrane Drugs Alcohol Group*. <https://doi.org/10.1002/14651858.CD009652>
- Dhalla, I.A., Mamdani, M.M., Sivilotti, M.L.A., Kopp, A., Qureshi, O., Juurlink, D.N., 2009. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. *CMAJ* 181, 891–896. <https://doi.org/10.1503/cmaj.090784>
- Drugs.ie, 2020. Overdose awareness during the COVID-19 pandemic [WWW Document]. URL http://www.drugs.ie/resources/covid/overdose_awareness_during_covid_19_pandemic/ (accessed 6.23.20).
- Eibl JK, Wilton AS, Franklyn AM, Kurdyak P, Marsh DC, 2019. Evaluating the Impact of Prescribed Versus Nonprescribed Benzodiazepine Use in Methadone Maintenance Therapy: Results From a Population-based Retrospective Cohort Study. *J. Addict. Med. J Addict Med.* <https://doi.org/10.1097/ADM.0000000000000476>
- EMCDDA, 2020. The implications of COVID-19 for people who use drugs (PWUD) and drug service providers [WWW Document]. URL https://www.emcdda.europa.eu/publications/topic-overviews/covid-19-and-people-who-use-drugs_en (accessed 6.20.20).
- EMCDDA, n.d. Take-home naloxone. EMCDDA.

- Garcia-Portilla, M.P., Bobes-Bascaran, M.T., Bascaran, M.T., Saiz, P.A., Bobes, J., 2014. Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack? *Br. J. Clin. Pharmacol.* 77, 272–284. <https://doi.org/10.1111/bcp.12031>
- Health Research Board, 2017. Drugnet Ireland Newsletter (No. 61). HRB, Dublin, Ireland.
- Health Service Executive, 2020. Guidance on Contingency Planning for People who use Drugs and COVID-19. Dublin, Ireland.
- Health Service Executive, n.d. Clinical Guidelines for Opiate Substitution therapy. HSE, Dublin, Ireland.
- Housing Act, 1988. . Office of the Attorney General.
- Keane, M., Collins, J., Csete, J., Duffin, T., 2018. Not Criminals: Underpinning a Health-led Approach to Drug Use. LSE, London.
- Kirsten Horsburgh, 2018. “My first 48 hours out” - Naloxone-on-Release: Guidelines for naloxone provision upon release from prison and other custodial settings. Scottish Drugs Forum, Glasgow.
- Lader, M., Tylee, A., Donoghue, J., 2009. Withdrawing Benzodiazepines in Primary Care. *CNS Drugs* 23, 19–34. <https://doi.org/10.2165/0023210-200923010-00002>
- Liebrez, M., Boesch, L., Stohler, R., Caflisch, C., 2010. Agonist substitution—a treatment alternative for high-dose benzodiazepine-dependent patients? *Addiction* 105, 1870–1874. <https://doi.org/10.1111/j.1360-0443.2010.02933.x>
- Lingford-Hughes, A.R., Welch, S., Nutt, D.J., 2004. Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, *Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology.* *J. Psychopharmacol. (Oxf.)* 18, 293–335. <https://doi.org/10.1177/026988110401800321>
- Nielsen, S., Dietze, P., Lee, N., Dunlop, A., Taylor, D., 2007. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. *Addiction* 102, 616–622. <https://doi.org/10.1111/j.1360-0443.2006.01731.x>
- O'Carroll, A., Private Communication 2015
- Parr, J.M., Kavanagh, D.J., Cahill, L., Mitchell, G., Young, R.M., 2009. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. *Addiction* 104, 13–24. <https://doi.org/10.1111/j.1360-0443.2008.02364.x>
- Progression Routes Initiative, 2011. Community Detoxification Protocols: Benzodiazepines. Dublin, Ireland.
- Soyka, M., 2010. To substitute or not substitute-optimal tactics for the management of benzodiazepine dependence. *Addiction* 105, 1876–1877. <https://doi.org/10.1111/j.1360-0443.2010.03087.x>
- Tjagvad, C., Clausen, T., Handal, M., Skurtveit, S., 2016. Benzodiazepine prescription for patients in treatment for drug use disorders: A nationwide cohort study in Denmark, 2000-2010. *BMC Psychiatry* 16, 168. <https://doi.org/10.1186/s12888-016-0881-y>
- Tyrer, P., 2010. Benzodiazepine Substitution for Dependent Patients - Going with the Flow. *Addiction* 105, 1875–1876. <https://doi.org/10.1111/j.1360-0443.2010.03067.x>

- United Nations, 2020. UNODC/WHO International Standards for the Treatment of Drug Use Disorders, https://www.unodc.org/documents/drug-prevention-and-treatment/UNODC-WHO_International_Standards_Treatment_Drug_Use_Disorders_April_2020.pdf. United Nations, Geneva and Vienna.
- Weizman, T., Gelkopf, M., Melamed, Y., Adelson, M., Bleich, A., 2003. Treatment of Benzodiazepine Dependence in Methadone Maintenance Treatment Patients: A Comparison of Two Therapeutic Modalities and the Role of Psychiatric Comorbidity. *Aust. N. Z. J. Psychiatry* 37, 458–463. <https://doi.org/10.1046/j.1440-1614.2003.01211.x>
- Wickes, W.A., Darke, S., Ross, J., 2000. Clobazam maintenance among methadone maintenance patients with problematic benzodiazepine use: five case studies. *Drug Alcohol Rev.* 19, 401–405. <https://doi.org/10.1080/713659419>
- World Health Organisation, 2020. COVID-19. WHO.
- World Health Organisation, 2014. Naloxone: A take-home antidote to drug overdose that saves lives [WWW Document]. WHO. URL <https://www.who.int/features/2014/naloxone/en/> (accessed 6.22.20).
- Yamamoto, T., Dargan, P., Dines, A., Yates, C., Heyerdahl, F., Hovda, K., Giraudon, I., Sedefov, R., Wood, D., 2019. Concurrent Use of Benzodiazepine by Heroin Users—What Are the Prevalence and the Risks Associated with This Pattern of Use? *J. Med. Toxicol.* 15, 4–11. <https://doi.org/10.1007/s13181-018-0674-4>